

From: [Scott, Dukes](#)
To: [Glaccum, David](#); [Taylor, Richele](#)
Cc: [Patel, Swati](#)
Subject: Investment analysts support agreement
Date: Friday, September 2, 2016 9:33:18 AM
Attachments: [09012016 Wells.pdf](#)
[ATT00001.htm](#)
[09012016 Mizuho.pdf](#)
[ATT00002.htm](#)
[09012016 UBS.pdf](#)
[ATT00003.htm](#)

Wells Fargo - SCG: Constructive Settlement Reached On Fixed-Price Option

Summary. On 9/1, SCG announced a settlement agreement with a number of intervenors including the South Carolina Office of Regulatory Staff (ORS) related to the company's election of the Fixed Price Option (FPO) for the new nuclear development (NND). Key provisions of the agreement include approval of an incremental \$831mm of capital costs and a modest reduction of the allowed ROE for NND to 10.25% from 10.5% to be applied (essentially) to new NND capital spend incurred post 6/30/16. Bottom line – we view the agreement as constructive and supportive of our positive rating on SCG - particularly as it relates to our longstanding thesis that there exists strong stakeholder support for new nuclear in SC. No change to our 16E & 17E of \$4.00 & \$4.25. We are modestly increasing our 18E to \$4.75 from \$4.65 to reflect an accelerated NND capex recovery vs. our prior assumption (model revision). We reiterate our Outperform rating and 12-18 month valuation range of \$78-80/share.

Next Steps. Since the settlement is not unanimous, there will be a public hearing [on 10/4](#). That being said, the settlement includes a number of highly influential parties including the ORS and an industrial users group. The SC Public Service Commission (PSC) is scheduled to issue a final decision by [11/28](#). Based on historical precedent, we would be surprised if the final order included any material modifications to the settlement. Along with the approved incremental capital costs and 10.25% ROE, other elements of the settlement include an approval of the updated schedule, which contemplates substantial completion dates of August 2019 (Unit 2) and August 2020 (Unit 3) and, separately, an agreement on the part of SCG to not request approval of any additional costs prior to [1/28/19](#).

EPS Outlook. Our 16-20E EPS are \$4.00, \$4.25, \$4.75, \$4.90 & \$5.15, which results in a 6-7% CAGR off the 2015 weather-normalized base of \$3.73. Based on our calculations, the 25 bp reduction in the ROE for prospective NND capex only had a modest \$0.01-0.03 negative impact on our 2018-20 EPS estimates. Our outlook assumes additional new equity of \$550mm during 2017 & 2018.

Valuation Range: \$78.00 to \$80.00

Our \$78-80/sh valuation range is based on a P/E multiple (apply a ~5% discount to the 17E Regulated Electric median of 17.5-18.0X to our 18E of \$4.75) and DDM analyses. Risks include regulatory and construction.

Investment Thesis:

We view SCG's ~10% P/E discount to be excessive as the above-average nuclear construction risk is partially offset by above-average EPS growth and a supportive regulatory environment, including timely BLRA recovery of new nuclear CapEx.

Mizuho - Da-Fix Means De-risk; Reiterate Buy; Remains a Top Pick

Event: SCGs flagship utility, South Carolina Electric & Gas, reached what we view to be a milestone settlement agreement related to its new nuclear build. Under the settlement, SCE&G will take a 25 basis point reduction in exchange for the ability to recover an additional \$831 million in higher nuclear costs, and fix the contract price with its EPC vendor, Westinghouse Electric. Total project cost becomes approximately \$7.7 billion. Importantly, the settlement supports the approval of the updated contract schedule which would have the two new units substantially completed by August 2019 and August 2020, meaning there are likely no additional delays. The key parties to the settlement include the S.C. Office of Regulatory Staff, key electric cooperatives, and the industrial user groups. Absent from the agreement are the Sierra Club, Coastal Carolina Conservation League, and CMC Steel. Upon first look, the settlement agreement mirrors exactly our expectations. As of this writing, SCG has not filed an 8-K with the complete settlement report.

Implication: The settlement agreement, if approved by the SC regulators, helps: (i) de-risk the story on many fronts but most importantly, by removing any variable price exposure SCE&G might have otherwise had with the nuclear build; (ii) reduce the discounted valuation; (iii) re-bases its earnings growth profile; (iv) allows investors to concentrate on a likely acceleration in the dividend growth rate towards the end of the decade to return to a 60% payout ratio; and (v) allows investors to concentrate on how SCG will redeploy the roughly \$550 million in annual cash flow from these two new nuclear units. Hearings on the proposed settlement are slated to begin [October 4, 2016](#). We expect regulatory approval on or around mid-November.

Expected Stock Reaction: POSITIVE

Our 2016, 2017, 2018, and 2019 EPS estimates remain unchanged at \$4.02, \$4.15, \$4.60, and \$5.00, respectively, which already reflect the fixed price option. Our 2018 estimate is approximately \$0.13 per share above current Street consensus (having inched up from \$4.40/sh.) as more analysts include the fixed price option. Our 2018 EPS estimate reflects \$500 million in secondary equity issuances in that year (using mid-year convention) to support the balance sheet as well as roughly \$100-125 million in annual DRIP (consistent with management disclosure). SCG previously articulated 4-6% EPS growth exclusive of the fixed price deal; thus, we expect the current 9% discount on our 2018E EPS to begin to abate as earnings expectations are re-based higher.

UBS - Fixing a Deal on a Fixed Price Contract

SCG files settlement with interveners on fixed price nuclear deal

Mgmt successfully filed a settlement with ORS and a variety of other SC parties as part of its petition to increase rates to reflect principally the costs associated with implementing a fixed price deal for its VC Summer nuclear expansion. Hearings are still scheduled for [Oct 4](#) with a decision from the PSC expected in ~Nov. We see the project as substantially de-risked with this deal; we note the updated CWIP figures reflecting this higher spend were already introduced with 2Q. We look for an update by [Oct 1st](#) on the final timing for Construction Milestone payments with Fluor, which could tweak CWIP on the project (hence EPS). The finalization of this schedule should allow for the SC PSC to have the final view on payments by the time it votes.

What are they giving up? No further capital cost increases pre '19

In turn, mgmt. commits to avoid further increases in capital costs pre [Jan 28, 2019](#), just a few months before the scheduled Aug 2019 in-service date of Unit 2 (slight delay from last order of Jun 2019). We note the deal includes interveners with a contingency for project delay of 18-

months+ (presumably to line up with the end of ~2020). Experts we've spoken to believe efforts appear under way to provide for a potential PTC qualification extension beyond the [12/31/2020](#) deadline (potentially indefinitely).

We remain concerned around future project delays

We are wary re progress on the site as hiring activities by Fluor ramp and overall productivity appears above 1.0. We believe the project could still be readily delayed, but the question is whether any such delay would be beyond the end of 2020. We note the order only limits the company's ability to file for further increases *until* 2019, rather than preventing it from doing so. From an investor perspective the limited ability to refile for the time being should substantially de-risk near-term EPS as the SCG will not seek deals beyond the scope defined. A deal was also reached in NC earlier this week.

Also locking in new nuclear ROE at reduced rate of 10.25% through build

Mgmt is also further reducing its ROE on the Summer project to 10.25% from 10.5% (already lowered from 11% from the last deal). Notably this is consistent with SCE&G's currently authorized ROE of 10.25% (to which it would have dropped once reaching inservice anyway). We are not surprised by this aspect of the deal; mgmt also used this lever in the last round of negotiations.

We expect the shares to trade up on deal announcement.

While not additive to 2Q disclosures on CWIP, we think the deal de-risks the shares. We note consensus remains conservative, with this latest deal allowing for positive estimate revisions (albeit offset in part by the slightly lower ROE). Ahead of final payment update [on 10/1](#), we maintain our estimates at the top end of mgmt's 4-6% EPS growth rate; our estimates are somewhat conservative to reflect the risk of future execution slip.

Barclays - SCG: Settlement Agreement for Fixed Price Option on New Nuclear

On September 1, SCE&G announced that it had entered into a settlement agreement with the South Carolina Office of Regulatory Staff, the Central Electric Power Cooperative Inc., The Electric Cooperatives of South Carolina, Inc., Frank Knapp Jr., and South Carolina Energy Users Committee related to SCE&G's petition to update construction and capital cost schedules, including SCE&G's election of the Fixed Price Option for the two new nuclear units under construction. The settlement agreement is subject to approval by the Public Service Commission of South Carolina. A public hearing on SCE&G's petition is scheduled to begin [October 4, 2016](#). The settlement agreement signifies that no contested issues exist among the settling parties and supports approval of the updated construction schedule. The settlement supports the inclusion of an additional \$831M in the capital cost schedule. In addition to supporting the new schedule and increased cost, the settling parties agreed to revised the allowed ROE from 10.50% down to 10.25%. The new ROE will be applied prospectively for all costs recovery sought on or [after January 1, 2017](#), until such time that the new nuclear units are completed. SCE&G also agreed not to file future requests to amend the capital cost schedule prior to [January 28, 2019](#).

We find this a constructive settlement that if approved will move to further limit the risk associated with nuclear new build project. The 25bp reduction in ROE is in line to better than expectations given the settlement for the last major cost and schedule change resulted in a 50bp reduction in allowed ROE. We await a final order to determine the profile of the

additional \$831M in capital costs along with any associated change in financing from debt and equity in support of the increased costs.

Bryant Potter | Investor Relations & Shareholder Services | SCANA Corporation |
Office [803.217.6916](tel:803.217.6916) | addison.potter@scana.com

September 1, 2016



Equity Research

SCANA Corporation

SCG: Constructive Settlement Reached On Fixed-Price Option

Outperform

Sector: Regulated Electric Utilities
Market Weight

Company Note

| | 2015A | 2016E | 2017E | |
|-----------|---------|----------|-------|---------|
| EPS | | Curr. | Prior | Curr. |
| Q1 (Mar.) | \$1.39 | \$1.23 A | NC | NE |
| Q2 (June) | 0.69 | 0.74 A | NC | NE |
| Q3 (Sep.) | 1.04 | 1.06 | NC | NE |
| Q4 (Dec.) | 0.69 | 0.97 | NC | NE |
| FY | \$3.81 | \$4.00 | NC | \$4.25 |
| CY | \$3.81 | \$4.00 | | \$4.25 |
| FY P/EPS | 18.4x | 17.5x | | 16.5x |
| Rev.(MM) | \$4,380 | \$4,556 | | \$4,741 |

Source: Company Data, Wells Fargo Securities, LLC estimates, and Reuters
NA = Not Available, NC = No Change, NE = No Estimate, NM = Not Meaningful
V = Volatile, * = Company is on the Priority Stock List

SCG's '16 weather-normalized EPS guidance is \$3.90-4.10.
YTD weather impact on electric margins is flat but led to a \$0.06 decline at GA sub in Q1.
Favorable weather versus normal provided a \$0.08 benefit in 2015.

• **Summary.** On 9/1, SCG announced a settlement agreement with a number of intervenors including the South Carolina Office of Regulatory Staff (ORS) related to the company's election of the Fixed Price Option (FPO) for the new nuclear development (NND). Key provisions of the agreement include approval of an incremental \$831mm of capital costs and a modest reduction of the allowed ROE for NND to 10.25% from 10.5% to be applied (essentially) to new NND capital spend incurred post 6/30/16. Bottom line – we view the agreement as constructive and supportive of our positive rating on SCG – particularly as it relates to our longstanding thesis that there exists strong stakeholder support for new nuclear in SC. No change to our 16E & 17E of \$4.00 & \$4.25. We are modestly increasing our 18E to \$4.75 from \$4.65 to reflect an accelerated NND capex recovery vs. our prior assumption (model revision). We reiterate our Outperform rating and 12-18 month valuation range of \$78-80/share.

• **Next Steps.** Since the settlement is not unanimous, there will be a public hearing on 10/4. That being said, the settlement includes a number of highly influential parties including the ORS and an industrial users group. The SC Public Service Commission (PSC) is scheduled to issue a final decision by 11/28. Based on historical precedent, we would be surprised if the final order included any material modifications to the settlement. Along with the approved incremental capital costs and 10.25% ROE, other elements of the settlement include an approval of the updated schedule, which contemplates substantial completion dates of August 2019 (Unit 2) and August 2020 (Unit 3) and, separately, an agreement on the part of SCG to not request approval of any additional costs prior to 1/28/19.

• **EPS Outlook.** Our 16-20E EPS are \$4.00, \$4.25, \$4.75, \$4.90 & \$5.15, which results in a 6-7% CAGR off the 2015 weather-normalized base of \$3.73. Based on our calculations, the 25 bp reduction in the ROE for prospective NND capex only had a modest \$0.01-0.03 negative impact on our 2018-20 EPS estimates. Our outlook assumes additional new equity of \$550mm during 2017 & 2018.

Valuation Range: \$78.00 to \$80.00

Our \$78-80/sh valuation range is based on a P/E multiple (apply a ~5% discount to the 17E Regulated Electric median of 17.5-18.0x to our 18E of \$4.75) and DDM analyses. Risks include regulatory and construction.

Investment Thesis:

We view SCG's ~10% P/E discount to be excessive as the above-average nuclear construction risk is partially offset by above-average EPS growth and a supportive regulatory environment, including timely BLRA recovery of new nuclear CapEx.

| | |
|-------------------------------|-------------|
| Ticker | SCG |
| Price (09/01/2016) | \$70.01 |
| 52-Week Range: | \$50-77 |
| Shares Outstanding: (MM) | 142.9 |
| Market Cap.: (MM) | \$10,004.4 |
| S&P 500: | 2,170.86 |
| Avg. Daily Vol.: | 644,406 |
| Dividend/Yield: | \$2.30/3.3% |
| LT Debt: (MM) | \$5,995.0 |
| LT Debt/Total Cap.: | 48.1% |
| ROE: | 10.0% |
| 3-5 Yr. Est. Growth Rate: | 6.0% |
| CY 2016 Est. P/EPS-to-Growth: | 2.9x |
| Last Reporting Date: | 07/28/2016 |
| | Before Open |

Source: Company Data, Wells Fargo Securities, LLC estimates, and Reuters

Neil Kalton, CFA, Senior Analyst
(314) 875-2051
neil.kalton@wellsfargo.com

Jonathan Reeder, Associate Analyst
(314) 875-2052
jonathan.reeder@wellsfargo.com

Sarah Akers, CFA, Senior Analyst
(314) 875-2040
sarah.akers@wellsfargo.com

Glen F. Pruitt, Associate Analyst
(314) 875-2047
glen.f.pruitt@wellsfargo.com

Please see page 3 for rating definitions, important disclosures and required analyst certifications

All estimates/forecasts are as of 09/01/16 unless otherwise stated.

Wells Fargo Securities, LLC does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of the report and investors should consider this report as only a single factor in making their investment decision.

Together we'll go far




Utilities

Company Description:

Headquartered in Cayce, South Carolina, SCANA's businesses include regulated electric and natural gas utility services, gas transmission and retail gas and energy marketing. The company's primary subsidiary, South Carolina Electric and Gas (SCE&G), serves 688,000 electric utility customers and 325,000 natural gas customers in central, southern, and southwestern portions of South Carolina. Public Service North Carolina serves 500,000 natural gas customers in north, central, Piedmont, and western parts of North Carolina. SCG is also involved in retail natural gas marketing in Georgia and wholesale energy marketing in the Southeast.

Required Disclosures

SCANA Corporation (SCG) 3-yr. Price Performance



Date

| Date | Published Price (\$) | Rating Code | Val. Rng. Low | Val. Rng. High | Close Price (\$) |
|------------|----------------------|-------------|---------------|----------------|------------------|
| 8/27/2013 | | Kelton | | | |
| 8/27/2013 | NA | 1 | 58.00 | 59.00 | 48.46 |
| 8/30/2013 | 48.10 | 1 | 54.00 | 55.00 | 48.12 |
| 3/17/2014 | 50.59 | 1 | 59.00 | 60.00 | 50.59 |
| 4/24/2014 | 52.56 | 1 | 60.00 | 61.00 | 52.56 |
| 6/30/2014 | 53.65 | 1 | 63.00 | 64.00 | 53.81 |
| 8/1/2014 | 50.88 | 1 | 60.00 | 61.00 | 50.86 |
| 12/16/2014 | 57.67 | 1 | 64.00 | 65.00 | 57.64 |
| 12/29/2014 | 62.27 | 1 | 69.00 | 70.00 | 63.18 |
| 2/17/2015 | 57.80 | 1 | 64.00 | 65.00 | 57.80 |
| 2/20/2015 | 58.27 | 1 | 63.00 | 64.00 | 58.30 |
| 3/9/2015 | 53.26 | 1 | 61.00 | 62.00 | 53.26 |
| 6/25/2015 | 50.70 | 1 | 57.00 | 58.00 | 50.22 |
| 7/30/2015 | 54.08 | 1 | 60.00 | 61.00 | 54.08 |
| 9/30/2015 | 55.12 | 1 | 61.00 | 62.00 | 56.26 |
| 10/30/2015 | 59.38 | 1 | 66.00 | 67.00 | 59.22 |
| 2/18/2016 | 65.80 | 1 | 73.00 | 74.00 | 65.80 |
| 3/31/2016 | 70.15 | 1 | 77.00 | 79.00 | 70.15 |
| 4/29/2016 | 67.81 | 1 | 74.00 | 76.00 | 68.69 |
| 6/5/2016 | 71.15 | 1 | 78.00 | 79.00 | 71.15 |
| 6/30/2016 | 74.97 | 1 | 81.00 | 83.00 | 75.66 |

Source: Wells Fargo Securities, LLC estimates and Reuters data

Symbol Key

- ▼ Rating Downgrade
- ▲ Rating Upgrade
- Valuation Range Change
- ◆ Initiation, Resumption, Drop or Suspend
- Analyst Change
- Split Adjustment

Rating Code Key

- 1 Outperform/Buy
- 2 Market Perform/Hold
- 3 Underperform/Sell
- SR Suspended
- NR Not Rated
- NE No Estimate

Additional Information Available Upon Request

Utilities**WELLS FARGO SECURITIES, LLC
EQUITY RESEARCH DEPARTMENT**

I certify that:

- 1) All views expressed in this research report accurately reflect my personal views about any and all of the subject securities or issuers discussed; and
- 2) No part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by me in this research report.

- Wells Fargo Securities, LLC maintains a market in the common stock of SCANA Corporation.
- Wells Fargo Securities, LLC or its affiliates intends to seek or expects to receive compensation for investment banking services in the next three months from SCANA Corporation.
- Wells Fargo Securities, LLC and/or its affiliates, have beneficial ownership of 1% or more of any class of the common stock of SCANA Corporation.
- SCANA Corporation currently is, or during the 12-month period preceding the date of distribution of the research report was, a client of Wells Fargo Securities, LLC. Wells Fargo Securities, LLC provided nonsecurities services to SCANA Corporation.
- Wells Fargo Securities, LLC received compensation for products or services other than investment banking services from SCANA Corporation in the past 12 months.
- Wells Fargo Securities, LLC or its affiliates has a significant financial interest in SCANA Corporation.
- Wells Fargo Securities, LLC or its affiliates intends to seek or expects to receive compensation for investment banking services in the next three months from an affiliate of SCANA Corporation.
- Wells Fargo Securities, LLC or its affiliates managed or co-managed a public offering of securities for an affiliate of SCANA Corporation within the past 12 months.
- Wells Fargo Securities, LLC or its affiliates received compensation for investment banking services from an affiliate of SCANA Corporation in the past 12 months.

SCG: Risks include regulatory and construction.

Wells Fargo Securities, LLC does not compensate its research analysts based on specific investment banking transactions. Wells Fargo Securities, LLC's research analysts receive compensation that is based upon and impacted by the overall profitability and revenue of the firm, which includes, but is not limited to investment banking revenue.

STOCK RATING

1=Outperform: The stock appears attractively valued, and we believe the stock's total return will exceed that of the market over the next 12 months. **BUY**

2=Market Perform: The stock appears appropriately valued, and we believe the stock's total return will be in line with the market over the next 12 months. **HOLD**

3=Underperform: The stock appears overvalued, and we believe the stock's total return will be below the market over the next 12 months. **SELL**

SECTOR RATING

O=Overweight: Industry expected to outperform the relevant broad market benchmark over the next 12 months.

M=Market Weight: Industry expected to perform in-line with the relevant broad market benchmark over the next 12 months.

U=Underweight: Industry expected to underperform the relevant broad market benchmark over the next 12 months.

VOLATILITY RATING

V = A stock is defined as volatile if the stock price has fluctuated by +/-20% or greater in at least 8 of the past 24 months or if the analyst expects significant volatility. All IPO stocks are automatically rated volatile within the first 24 months of trading.

As of: September 1, 2016

41% of companies covered by Wells Fargo Securities, LLC Equity Research are rated Outperform.

Wells Fargo Securities, LLC has provided investment banking services for 37% of its Equity Research Outperform-rated companies.

56% of companies covered by Wells Fargo Securities, LLC Equity Research are rated Market Perform.

Wells Fargo Securities, LLC has provided investment banking services for 25% of its Equity Research Market Perform-rated companies.

3% of companies covered by Wells Fargo Securities, LLC Equity Research are rated Underperform.

Wells Fargo Securities, LLC has provided investment banking services for 3% of its Equity Research Underperform-rated companies.

Important Disclosure for International Clients

EEA – The securities and related financial instruments described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. For recipients in the EEA, this report is distributed by Wells Fargo Securities International Limited (“WFSIL”). WFSIL is a U.K. incorporated investment firm authorized and regulated by the Financial Conduct Authority. For the purposes of Section 21 of the UK Financial Services and Markets Act 2000 (“the Act”), the content of this report has been approved by WFSIL a regulated person under the Act. WFSIL does not deal with retail clients as defined in the Markets in Financial Instruments Directive 2007. The FCA rules made under the Financial Services and Markets Act 2000 for the protection of retail clients will therefore not apply, nor will the Financial Services Compensation Scheme be available. This report is not intended for, and should not be relied upon by, retail clients.

Australia – Wells Fargo Securities, LLC is exempt from the requirements to hold an Australian financial services license in respect of the financial services it provides to wholesale clients in Australia. Wells Fargo Securities, LLC is regulated under U.S. laws which differ from Australian laws. Any offer or documentation provided to Australian recipients by Wells Fargo Securities, LLC in the course of providing the financial services will be prepared in accordance with the laws of the United States and not Australian laws.

Canada – This report is distributed in Canada by Wells Fargo Securities Canada, Ltd., a registered investment dealer in Canada and member of the Investment Industry Regulatory Organization of Canada (IIROC) and Canadian Investor Protection Fund (CIPF). Wells Fargo Securities, LLC’s research analysts may participate in company events such as site visits but are generally prohibited from accepting payment or reimbursement by the subject companies for associated expenses unless pre-authorized by members of Research Management.

Hong Kong – This report is issued and distributed in Hong Kong by Wells Fargo Securities Asia Limited (“WFSAL”), a Hong Kong incorporated investment firm licensed and regulated by the Securities and Futures Commission of Hong Kong (“the SFC”) to carry on types 1, 4, 6 and 9 regulated activities (as defined in the Securities and Futures Ordinance (Cap. 571 of The Laws of Hong Kong), “the SFO”). This report is not intended for, and should not be relied on by, any person other than professional investors (as defined in the SFO). Any securities and related financial instruments described herein are not intended for sale, nor will be sold, to any person other than professional investors (as defined in the SFO). The author or authors of this report is or are not licensed by the SFC. Professional investors who receive this report should direct any queries regarding its contents to Mark Jones at WFSAL (email: wfsalresearch@wellsfargo.com).

Japan – This report is distributed in Japan by Wells Fargo Securities (Japan) Co., Ltd, registered with the Kanto Local Finance Bureau to conduct broking and dealing of type 1 and type 2 financial instruments and agency or intermediary service for entry into investment advisory or discretionary investment contracts. This report is intended for distribution only to professional investors (Tokutei Toushika) and is not intended for, and should not be relied upon by, ordinary customers (Ippan Toushika).

The ratings stated on the document are not provided by rating agencies registered with the Financial Services Agency of Japan (JFSA) but by group companies of JFSA-registered rating agencies. These group companies may include Moody’s Investors Services Inc., Standard & Poor’s Rating Services and/or Fitch Ratings. Any decisions to invest in securities or transactions should be made after reviewing policies and methodologies used for assigning credit ratings and assumptions, significance and limitations of the credit ratings stated on the respective rating agencies’ websites.

About Wells Fargo Securities

Wells Fargo Securities is the trade name for the capital markets and investment banking services of Wells Fargo & Company and its subsidiaries, including but not limited to Wells Fargo Securities, LLC, a U.S. broker-dealer registered with the U.S. Securities and Exchange Commission and a member of NYSE, FINRA, NFA and SIPC, Wells Fargo Prime Services, LLC, a member of FINRA, NFA and SIPC, Wells Fargo Securities Canada, Ltd., a member of IIROC and CIPF, Wells Fargo Bank, N.A. and Wells Fargo Securities International Limited, authorized and regulated by the Financial Conduct Authority.

This report is for your information only and is not an offer to sell, or a solicitation of an offer to buy, the securities or instruments named or described in this report. Interested parties are advised to contact the entity with which they deal, or the entity that provided this report to them, if they desire further information. The information in this report has been obtained or derived from sources believed by Wells Fargo Securities, LLC, to be reliable, but Wells Fargo Securities, LLC does not represent that this information is accurate or complete. Any opinions or estimates contained in this report represent the judgment of Wells Fargo Securities, LLC, at this time, and are subject to change without notice. All Wells Fargo Securities research reports published by its Global Research Department (“WFS Research”) are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Additional distribution may be done by sales personnel via email, fax or regular mail. Clients may also receive our research via third party vendors. Not all research content is redistributed to our clients or available to third-party aggregators, nor is WFS Research responsible for the redistribution of our research by third party aggregators. For research or other data available on a particular security, please contact your sales representative or go to <http://www.wellsfargoresearch.com>. For the purposes of the U.K. Financial Conduct Authority’s rules, this report constitutes impartial investment research. Each of Wells Fargo Securities, LLC and Wells Fargo Securities International Limited is a separate legal entity and distinct from affiliated banks. Copyright © 2016 Wells Fargo Securities, LLC

| |
|---|
| SECURITIES: NOT FDIC-INSURED/NOT BANK-GUARANTEED/MAY LOSE VALUE |
|---|

SCANA Corporation (SCG)

Da-Fix Means De-risk; Reiterate Buy; Remains a Top Pick

Event: SCGs flagship utility, South Carolina Electric & Gas, reached what we view to be a milestone settlement agreement related to its new nuclear build. Under the settlement, SCE&G will take a 25 basis point reduction in exchange for the ability to recover an additional \$831 million in higher nuclear costs, and fix the contract price with its EPC vendor, Westinghouse Electric. Total project cost becomes approximately \$7.7 billion. Importantly, the settlement supports the approval of the updated contract schedule which would have the two new units substantially completed by August 2019 and August 2020, meaning there are likely no additional delays. The key parties to the settlement include the S.C. Office of Regulatory Staff, key electric cooperatives, and the industrial user groups. Absent from the agreement are the Sierra Club, Coastal Carolina Conservation League, and CMC Steel. Upon first look, the settlement agreement mirrors exactly our expectations. As of this writing, SCG has not filed an 8-K with the complete settlement report.


Implication: The settlement agreement, if approved by the SC regulators, helps: (i) de-risk the story on many fronts but most importantly, by removing any variable price exposure SCE&G might have otherwise had with the nuclear build; (ii) reduce the discounted valuation; (iii) re-bases its earnings growth profile; (iv) allows investors to concentrate on a likely acceleration in the dividend growth rate towards the end of the decade to return to a 60% payout ratio; and (v) allows investors to concentrate on how SCG will redeploy the roughly \$550 million in annual cash flow from these two new nuclear units. Hearings on the proposed settlement are slated to begin October 4, 2016. We expect regulatory approval on or around mid-November.

Expected Stock Reaction: POSITIVE

Our 2016, 2017, 2018, and 2019 EPS estimates remain unchanged at \$4.02, \$4.15, \$4.60, and \$5.00, respectively, which already reflect the fixed price option. Our 2018 estimate is approximately \$0.13 per share above current Street consensus (having inched up from \$4.40/sh.) as more analysts include the fixed price option. Our 2018 EPS estimate reflects \$500 million in secondary equity issuances in that year (using mid-year convention) to support the balance sheet as well as roughly \$100-125 million in annual DRIP (consistent with management disclosure). SCG previously articulated 4-6% EPS growth exclusive of the fixed price deal; thus, we expect the current 9% discount on our 2018E EPS to begin to abate as earnings expectations are re-based higher.

Energy Research
Power, Utilities & Alternative Energy
Company Flash

| | |
|-----------------------|----------------|
| Rating | Buy |
| Previous Rating | No Change |
| Price (9/01) | \$70.01 |
| Price Target | \$84.00 |
| Previous Price Target | No Change |



James von Riesenmann
Managing Director, Americas Research
212-205-7857
james.vonriesemann@us.mizuho-sc.com

PLEASE REFER TO PAGE 3 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA Inc. does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Price Target Calculation and Key Risks

Our 12-month \$84 per share price target is based on a 16.8x P/E multiple on 2018. We also use sum of the parts, single- and two-stage DDM, and price-to-book to help triangulate valuation. Key risks include execution risk with the nuclear project; the cost of building the two new nuclear units is roughly 75% of SCGs market cap today and once complete, will represent nearly one-half the earnings power and two-thirds of the cash flow. General risks include economic conditions, a changing regulatory environment, and changes in interest rates.

IMPORTANT DISCLOSURES

The disclosures for the subject companies of this report as well as the disclosures for Mizuho Securities USA Inc. entire coverage universe can be found at <https://msusa.bluematrix.com/sellside/Disclosures.action> or obtained by contacting EQSupervisoryAnalystUS@us.mizuho-sc.com or via postal mail at Equity Research Editorial Department, Mizuho Securities USA Inc., 320 Park Avenue, 12th Floor, New York NY, 10022.

Ownership Disclosures and Material Conflicts of Interest or Position as Officer or Director

None

Receipt of Compensation

Mizuho Securities USA Inc. and its affiliates makes a market in the following securities: SCANA Corporation

The compensation of the research analyst writing this report, in whole or part, is based on MSUSA's annual revenue and earnings and is not directly related to any specific investment banking compensation. MSUSA's internal policies and procedures prohibit research analysts from receiving compensation from companies covered in the research reports.

Regulation Analyst Certification (AC)

I, James von Riesemann, hereby certify that the views expressed in this research report accurately reflect my personal views about any and all the subject companies. No part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.

Rating Definitions


Mizuho Securities USA investment ratings are based on the following definitions. Anticipated share price change is based on a 6- to 12-month time frame. Return expectation excludes dividends.

| | |
|----------------------|---|
| Buy: | Stocks for which the anticipated share price appreciation exceeds 10%. |
| Neutral: | Stocks for which the anticipated share price appreciation is within 10% of the share price. |
| Underperform: | Stocks for which the anticipated share price falls by 10% or more. |
| RS: | Rating Suspended - rating and price objective temporarily suspended. |
| NR: | No Rating - not covered, and therefore not assigned a rating. |

Rating Distribution

| (As of 9/01) | % of coverage | IB service past 12 mo |
|---------------------|---------------|-----------------------|
| Buy (Buy) | 43.00% | 35.96% |
| Hold (Neutral) | 56.04% | 26.72% |
| Sell (Underperform) | 0.97% | 50.00% |

For disclosure purposes only (NYSE and FINRA ratings distribution requirements), our Buy, Neutral and Underperform ratings are displayed as Buy, Hold and Sell, respectively.



For additional information: Please log on to <http://www.mizuhosecurities.com/us> or write to Mizuho Securities USA Inc. 320 Park Ave, 12th FL, New York, NY 10020.

Disclaimers

This report has been prepared by Mizuho Securities USA Inc. ("MSUSA"), a subsidiary of Mizuho Americas LLC, solely for the purpose of supplying information to the clients of MSUSA and/or its affiliates to whom it is distributed. This report is not, and should not be construed as, a solicitation or offer to buy or sell any securities or related financial products.

This report has been prepared by MSUSA solely from publicly available information. The information contained herein is believed to be reliable but has not been independently verified. MSUSA makes no guarantee, representation or warranty, and MSUSA, MHSC and/or their affiliates, directors, employees or agents accept no responsibility or liability whatsoever as to the accuracy, completeness or appropriateness of such information or for any loss or damage arising from the use or further communication of this report or any part of it. Information contained herein may not be current due to, among other things, changes in the financial markets or economic environment. Opinions reflected in this report are subject to change without notice.

This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. The report has been prepared without regard to the individual financial circumstances, needs or objectives of persons who receive it. The securities and investments related to the securities discussed in this report may not be suitable for all investors, and the report is intended for distribution to Institutional Investors. Readers should independently evaluate particular investments and strategies, and seek the advice of a financial adviser before making any investment or entering into any transaction in relation to the securities mentioned in this report.

MSUSA has no legal responsibility to any investor who directly or indirectly receives this material. Investment decisions are to be made by and remain as the sole responsibility of the investor. Investment involves risks. The price of securities may go down as well as up, and under certain circumstances investors may sustain total loss of investment. Past performance should not be taken as an indication or guarantee of future performance. Unless otherwise attributed, forecasts of future performance represent analysts' estimates based on factors they consider relevant. Actual performance may vary. Consequently, no express or implied warranty can be made regarding future performance.

Any references in this report to Mizuho Financial Group, Inc. ("MHFG"), MHSC and/or its affiliates are based only on publicly available information. The authors of this report are prohibited from using or even obtaining any insider information. As a direct subsidiary of Mizuho Americas LLC and indirect subsidiary of MHFG, MSUSA does not, as a matter of corporate policy, cover MHFG or MHSC for investment recommendation purposes.

MSUSA or other companies affiliated with MHFG, Mizuho Americas LLC or MHSC, together with their respective directors and officers, may have or take positions in the securities mentioned in this report, or derivatives of such securities or other securities issued by companies mentioned in this report, for their own account or the accounts of others, or enter into transactions contrary to any recommendations contained herein, and also may perform or seek to perform broking and other investment or securities related services for the companies mentioned in this report as well as other parties generally.

Restrictions on Distribution

This report is not directed to, or intended for distribution to or use by, any person who is a citizen or resident of, or entity located in, any locality, territory, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to or restricted by law or regulation. Persons or entities into whose possession this report comes should inform themselves about and observe such restrictions.

United States: Mizuho Securities USA Inc., a subsidiary of Mizuho Americas LLC, 320 Park Avenue, 12th Floor, New York, NY 10022, USA, contact number +1-212-209-9300, distributes or approves the distribution of this report in the United States and takes responsibility for it. Any transaction by a US investor resulting from the information contained in this report may be effected only through MSUSA. Interested US investors should contact their MSUSA sales representative.

United Kingdom/European Economic Area: This report is distributed or has been approved for issue and distribution in the UK by Mizuho International plc ("MHI"), Mizuho House, 30 Old Bailey, London EC4M 7AU, a member of the MHSC Group. MHI is authorized and regulated by the Financial Services Authority and is a member of the London Stock Exchange. For the avoidance of doubt this report is not intended for retail clients. This report may be distributed in other member states of the European Union.

Japan: This report is distributed in Japan by Mizuho Securities Co., Ltd. ("MHSC"), Otemachi First Square Otemachi 1-chome, Chiyoda-ku, Tokyo 100-0004, Japan. Registered Financial Instruments Firm, No. 94 (Kinsho), issued by the Director, Kanto Local Finance Bureau. MHSC is a member of the Japan Securities Dealers Association, the Japan Securities Investment Advisers Association and the Financial Futures Association of Japan, and the Type II Financial Instruments Firms Association.

Singapore: This report is distributed or has been approved for distribution in Singapore by Mizuho Securities (Singapore) Pte. Ltd. ("MHSS"), a member of the MHSC Group, which is regulated by the Monetary Authority of Singapore. Any research report produced by a foreign Mizuho entity, analyst or affiliate is distributed in Singapore only to "Institutional Investors," "Expert Investors" or "Accredited Investors" as defined in the Securities and Futures Act, Chap. 289 of Singapore. Any matters arising from, or in connection with this material, should be brought to the attention of MHSS.

Hong Kong: This report is being distributed in Hong Kong by Mizuho Securities Asia Limited ("MHSA"), a member of the MHSC Group, which is licensed and regulated by the Hong Kong Securities and Futures Commission.

Australia: This report is being distributed in Australia by MHSA, which is exempted from the requirement to hold an Australian financial services license under the Corporation Act 2001 ("CA") in respect of the financial services provided to the recipients. MHSA is regulated by the Securities and Futures Commission under the laws of Hong Kong, which differ from Australian laws. Distribution of this report is intended only for recipients who are "wholesale clients" within the meaning of the CA.

If you do not wish to receive our reports in the future, please contact your sales person and request to be removed from receiving this distribution.

© Mizuho Securities USA Inc. All Rights Reserved 2016. This document may not be altered, reproduced or redistributed, or passed on to any other party, in whole or in part, without the prior written consent of Mizuho Securities USA Inc.

First Read

SCANA Corp.

Fixing a Deal on a Fixed Price Contract

SCG files settlement with interveners on fixed price nuclear deal

Mgmt successfully filed a [settlement with ORS](#) and a variety of other SC parties as part of its petition to increase rates to reflect principally the costs associated with implementing a fixed price deal for its VC Summer nuclear expansion. Hearings are still scheduled for Oct 4 with a decision from the PSC expected in ~Nov. We see the project as substantially de-risked with this deal; we note the updated CWIP figures reflecting this higher spend were already introduced with 2Q. We look for an update by Oct 1st on the final timing for Construction Milestone payments with Fluor, which could tweak CWIP on the project (hence EPS). The finalization of this schedule should allow for the SC PSC to have the final view on payments by the time it votes.

What are they giving up? No further capital cost increases pre '19

In turn, mgmt. commits to avoid further increases in capital costs pre Jan 28, 2019, just a few months before the scheduled Aug 2019 in-service date of Unit 2 (slight delay from last order of Jun 2019). We note the deal includes interveners with a contingency for project delay of 18-months+ (presumably to line up with the end of ~2020). Experts we've spoken to believe efforts appear under way to provide for a potential PTC qualification extension beyond the 12/31/2020 deadline (potentially indefinitely).

We remain concerned around future project delays

We are wary re progress on the site as hiring activities by Fluor ramp and overall productivity appears above 1.0. We believe the project could still be readily delayed, but the question is whether any such delay would be beyond the end of 2020. We note the order only limits the company's ability to file for further increases *until* 2019, rather than preventing it from doing so. From an investor perspective the limited ability to refile for the time being should substantially de-risk near-term EPS as the SCG will not seek deals beyond the scope defined. A deal was also reached in NC earlier this week.

Also locking in new nuclear ROE at reduced rate of 10.25% through build

Mgmt is also further reducing its ROE on the Summer project to 10.25% from 10.5% (already lowered from 11% from the last deal). Notably this is consistent with SCE&G's currently authorized ROE of 10.25% (to which it would have dropped once reaching in-service anyway). We are not surprised by this aspect of the deal; mgmt also used this lever in the last round of negotiations.

We expect the shares to trade up on deal announcement.

While not additive to 2Q disclosures on CWIP, we think the deal de-risks the shares. We note consensus remains conservative, with this latest deal allowing for positive estimate revisions (albeit offset in part by the slightly lower ROE). Ahead of final payment update on 10/1, we maintain our estimates at the top end of mgmt's 4-6% EPS growth rate; our estimates are somewhat conservative to reflect the risk of future execution slip.

Equities

Americas
Electric Utilities

12-month rating **Neutral**

12m price target **US\$76.00**

Price **US\$70.01**

RIC: SCG.N BBG: SCG US

Trading data and key metrics

52-wk range US\$76.12-50.51

Market cap. US\$10.0bn

Shares o/s 143m (COM)

Free float 90%

Avg. daily volume ('000) 262

Avg. daily value (m) US\$19.1

Common s/h equity (12/16E) US\$5.69bn

P/BV (12/16E) 1.8x

Net debt / EBITDA (12/16E) 4.5x

EPS (UBS, diluted) (US\$)

| | 12/16E | |
|--------|--------|-------|
| | UBS | Cons. |
| Q1 | 1.23 | 1.23 |
| Q2 | 0.74 | 0.74 |
| Q3E | 1.18 | 1.05 |
| Q4E | 0.88 | 0.91 |
| 12/16E | 4.03 | 3.96 |
| 12/17E | 4.32 | 4.16 |
| 12/18E | 4.60 | 4.44 |

Julien Dumoulin-Smith

Analyst

julien.dumoulin-smith@ubs.com

+1-212-713 9848

Jeremiah Booream, CFA

Associate Analyst

jeremiah.booream@ubs.com

+1-212-713 4105

| Highlights (US\$m) | 12/13 | 12/14 | 12/15 | 12/16E | 12/17E | 12/18E | 12/19E | 12/20E |
|---------------------------|---------|---------|---------|---------|---------|---------|---------|---------|
| Revenues | 4,495 | 4,951 | 4,380 | 5,116 | 5,291 | 5,435 | 5,587 | 5,714 |
| EBIT (UBS) | 991 | 1,098 | 1,116 | 1,275 | 1,357 | 1,426 | 1,511 | 1,572 |
| Net earnings (UBS) | 471 | 538 | 545 | 576 | 623 | 664 | 704 | 721 |
| EPS (UBS, diluted) (US\$) | 3.39 | 3.79 | 3.81 | 4.03 | 4.32 | 4.60 | 4.88 | 5.00 |
| DPS (US\$) | 2.03 | 2.10 | 2.18 | 2.28 | 2.38 | 2.49 | 2.59 | 2.69 |
| Net (debt) / cash | (5,688) | (6,478) | (6,353) | (7,496) | (8,382) | (8,902) | (9,329) | (9,530) |
| Profitability/valuation | 12/13 | 12/14 | 12/15 | 12/16E | 12/17E | 12/18E | 12/19E | 12/20E |
| EBIT margin % | 22.0 | 22.2 | 25.5 | 24.9 | 25.7 | 26.2 | 27.1 | 27.5 |
| ROIC (EBIT) % | 12.0 | 12.3 | 11.9 | 12.5 | 11.8 | 11.3 | 11.2 | 11.1 |
| EV/EBITDA (core) x | 9.1 | 9.2 | 8.2 | 8.9 | 10.7 | 10.2 | 9.7 | 9.3 |
| P/E (UBS, diluted) x | 14.4 | 13.6 | 14.7 | 17.4 | 16.2 | 15.2 | 14.4 | 14.0 |
| Equity FCF (UBS) yield % | 2.3 | (2.0) | 1.5 | (7.7) | (4.2) | (0.1) | 2.4 | 5.1 |
| Net dividend yield % | 4.2 | 4.1 | 3.9 | 3.3 | 3.4 | 3.6 | 3.7 | 3.8 |

Source: Company accounts, Thomson Reuters, UBS estimates. Metrics marked as (UBS) have had analyst adjustments applied. Valuations: based on an average share price that year, (E): based on a share price of US\$70.01 on 01 Sep 2016 19:38 EDT

Forecast returns

| | |
|-----------------------------|--------|
| Forecast price appreciation | +8.6% |
| Forecast dividend yield | 3.4% |
| Forecast stock return | +12.0% |
| Market return assumption | 5.8% |
| Forecast excess return | +6.2% |

Valuation Method and Risk Statement

Factors that could prevent SCANA from achieving our earnings, cash flow, and price target objectives include: adverse weather conditions; changes in the regional power regulatory environment; adverse regulatory decisions in its various states jurisdictions (primarily SC, NC, and GA) as well as from the federal regulator, FERC; interest rate & capital market risks; slowdown in regional economy; risks associated with operating nuclear units; more stringent environment regulation; and the impact that changes in commodity prices could have on the unhedged portion of its competitive gas business, SCANA Energy. An added risk is the corresponding construction and financial risk associated with its proposed new nuclear units at the V.C. Summer facility. We value SCG on a SOTP using a -5% discount to the peer utility 2018E P/E multiple.

Required Disclosures

This report has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission. UBS acts or may act as principal in the debt securities (or in related derivatives) that may be the subject of this report. This recommendation was finalized on: 02 September 2016 09:41 AM GMT.

Analyst Certification: Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

UBS Investment Research: Global Equity Rating Definitions

| 12-Month Rating | Definition | Coverage ¹ | IB Services ² |
|-------------------|---|-----------------------|--------------------------|
| Buy | FSR is > 6% above the MRA. | 47% | 32% |
| Neutral | FSR is between -6% and 6% of the MRA. | 38% | 25% |
| Sell | FSR is > 6% below the MRA. | 15% | 21% |
| Short-Term Rating | Definition | Coverage ³ | IB Services ⁴ |
| Buy | Stock price expected to rise within three months from the time the rating was assigned because of a specific catalyst or event. | <1% | <1% |
| Sell | Stock price expected to fall within three months from the time the rating was assigned because of a specific catalyst or event. | <1% | <1% |

Source: UBS. Rating allocations are as of 30 June 2016.

1:Percentage of companies under coverage globally within the 12-month rating category.

2:Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided within the past 12 months.

3:Percentage of companies under coverage globally within the Short-Term rating category.

4:Percentage of companies within the Short-Term rating category for which investment banking (IB) services were provided within the past 12 months.

KEY DEFINITIONS: **Forecast Stock Return (FSR)** is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months. **Market Return Assumption (MRA)** is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium). **Under Review (UR)** Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation. **Short-Term Ratings** reflect the expected near-term (up to three months) performance of the stock and do not reflect any change in the fundamental view or investment case. **Equity Price Targets** have an investment horizon of 12 months.

EXCEPTIONS AND SPECIAL CASES: **UK and European Investment Fund ratings and definitions are:** **Buy:** Positive on factors such as structure, management, performance record, discount; **Neutral:** Neutral on factors such as structure, management, performance record, discount; **Sell:** Negative on factors such as structure, management, performance record, discount. **Core Banding Exceptions (CBE):** Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Company Disclosures table in the relevant research piece.

Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/qualified as research analysts with FINRA. Such analysts may not be associated persons of UBS Securities LLC and therefore are not subject to the FINRA restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.

UBS Securities LLC: Julien Dumoulin-Smith; Jeremiah Booream, CFA.

Company Disclosures

| Company Name | Reuters | 12-month rating | Short-term rating | Price | Price date |
|---|---------|-----------------|-------------------|-----------|-------------|
| SCANA Corp. ^{2, 4, 5, 6, 7, 16} | SCG.N | Neutral | N/A | US\$70.01 | 01 Sep 2016 |


Source: UBS. All prices as of local market close.

Ratings in this table are the most current published ratings prior to this report. They may be more recent than the stock pricing date

2. UBS AG, its affiliates or subsidiaries has acted as manager/co-manager in the underwriting or placement of securities of this company/entity or one of its affiliates within the past 12 months.
4. Within the past 12 months, UBS AG, its affiliates or subsidiaries has received compensation for investment banking services from this company/entity or one of its affiliates.
5. UBS AG, its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from this company/entity within the next three months.
6. This company/entity is, or within the past 12 months has been, a client of UBS Securities LLC, and investment banking services are being, or have been, provided.
7. Within the past 12 months, UBS Securities LLC and/or its affiliates have received compensation for products and services other than investment banking services from this company/entity.
16. UBS Securities LLC makes a market in the securities and/or ADRs of this company.

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report. For a complete set of disclosure statements associated with the companies discussed in this report, including information on valuation and risk, please contact UBS Securities LLC, 1285 Avenue of Americas, New York, NY 10019, USA, Attention: Investment Research.

SCANA Corp. (US\$)



Source: UBS; as of 01 Sep 2016

Global Disclaimer

This document has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

Global Research is provided to our clients through UBS Neo and, in certain instances, UBS.com (each a "System"). It may also be made available through third party vendors and distributed by UBS and/or third parties via e-mail or alternative electronic means. The level and types of services provided by Global Research to a client may vary depending upon various factors such as a client's individual preferences as to the frequency and manner of receiving communications, a client's risk profile and investment focus and perspective (e.g., market wide, sector specific, long-term, short-term, etc.), the size and scope of the overall client relationship with UBS and legal and regulatory constraints.

All Global Research is available on UBS Neo. Please contact your UBS sales representative if you wish to discuss your access to UBS Neo.

When you receive Global Research through a System, your access and/or use of such Global Research is subject to this Global Research Disclaimer and to the terms of use governing the applicable System.

When you receive Global Research via a third party vendor, e-mail or other electronic means, your use shall be subject to this Global Research Disclaimer and to UBS's Terms of Use/Disclaimer (<http://www.ubs.com/global/en/legalinfo2/disclaimer.html>). By accessing and/or using Global Research in this manner, you are indicating that you have read and agree to be bound by our Terms of Use/Disclaimer. In addition, you consent to UBS processing your personal data and using cookies in accordance with our Privacy Statement (<http://www.ubs.com/global/en/legalinfo2/privacy.html>) and cookie notice (<http://www.ubs.com/global/en/homepage/cookies/cookie-management.html>).

If you receive Global Research, whether through a System or by any other means, you agree that you shall not copy, revise, amend, create a derivative work, transfer to any third party, or in any way commercially exploit any UBS research provided via Global Research or otherwise, and that you shall not extract data from any research or estimates provided to you via Global Research or otherwise, without the prior written consent of UBS.

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction. It is published solely for information purposes; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in this document ("the Information"), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party.

Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. Investments involve risks, and investors should exercise prudence and their own judgement in making their investment decisions. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the Information.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

This document and the Information are produced by UBS as part of its research function and are provided to you solely for general background information. UBS has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. In no circumstances may this document or any of the Information be used for any of the following purposes:

- (i) valuation or accounting purposes;
- (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or
- (iii) to measure the performance of any financial instrument.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for any of the above purposes or otherwise rely upon this document or any of the Information.

UBS has policies and procedures, which include, without limitation, independence policies and permanent information barriers, that are intended, and upon which UBS relies, to manage potential conflicts of interest and control the flow of information within divisions of UBS and among its subsidiaries, branches and affiliates. For further information on the ways in which UBS manages conflicts and maintains independence of its research products, historical performance information and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures.

Research will initiate, update and cease coverage solely at the discretion of UBS Investment Bank Research Management, which will also have sole discretion on the timing and frequency of any published research product. The analysis contained in this document is based on numerous assumptions. All material information in relation to published research reports, such as valuation methodology, risk statements, underlying assumptions (including sensitivity analysis of those assumptions), ratings history etc. as required by the Market Abuse Regulation, can be found on NEO. Different assumptions could result in materially different results.

The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS Investment Bank as a whole, of which investment banking, sales and trading are a part, and UBS's subsidiaries, branches and affiliates as a whole.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

United Kingdom and the rest of Europe: Except as otherwise specified herein, this material is distributed by UBS Limited to persons who are eligible counterparties or professional clients. UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. **France:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities France S.A. UBS Securities France S.A. is regulated by the ACPR (Autorité de Contrôle Prudentiel et de Résolution) and the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities France S.A. has contributed to this document, the document is also deemed to have been prepared by UBS Securities France S.A. **Germany:** Prepared by UBS Limited and distributed by UBS Limited and UBS Deutschland AG. UBS Deutschland AG is regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). **Spain:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities España SV, SA. UBS Securities España SV, SA is regulated by the Comisión Nacional del Mercado de Valores (CNMV). **Turkey:**

Distributed by UBS Limited. No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey. UBS AG is not licensed by the Turkish Capital Market Board under the provisions of the Capital Market Law (Law No. 6362). Accordingly, neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the Capital Market Board. However, according to article 15 (d) (ii) of the Decree No. 32, there is no restriction on the purchase or sale of the securities abroad by residents of the Republic of Turkey.

Poland: Distributed by UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce regulated by the Polish Financial Supervision Authority. Where an analyst of UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce has contributed to this document, the document is also deemed to have been prepared by UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce.

Russia: Prepared and distributed by UBS Bank (OOO).

Switzerland: Distributed by UBS AG to persons who are institutional investors only. UBS AG is regulated by the Swiss Financial Market Supervisory Authority (FINMA).

Italy: Prepared by UBS Limited and distributed by UBS Limited and UBS Limited, Italy Branch. Where an analyst of UBS Limited, Italy Branch has contributed to this document, the document is also deemed to have been prepared by UBS Limited, Italy Branch.

South Africa: Distributed by UBS South Africa (Pty) Limited (Registration No. 1995/011140/07), an authorised user of the JSE and an authorised Financial Services Provider (FSP 7328).

Israel: This material is distributed by UBS Limited. UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. UBS Securities Israel Ltd is a licensed Investment Marketer that is supervised by the Israel Securities Authority (ISA). UBS Limited and its affiliates incorporated outside Israel are not licensed under the Israeli Advisory Law. UBS Limited is not covered by insurance as required from a licensee under the Israeli Advisory Law. UBS may engage among others in issuance of Financial Assets or in distribution of Financial Assets of other issuers for fees or other benefits. UBS Limited and its affiliates may prefer various Financial Assets to which they have or may have Affiliation (as such term is defined under the Israeli Advisory Law). Nothing in this Material should be considered as investment advice under the Israeli Advisory Law. This Material is being issued only to and/or is directed only at persons who are Eligible Clients within the meaning of the Israeli Advisory Law, and this material must not be relied on or acted upon by any other persons.

Saudi Arabia: This document has been issued by UBS AG (and/or any of its subsidiaries, branches or affiliates), a public company limited by shares, incorporated in Switzerland with its registered offices at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH-8001 Zurich. This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a Saudi closed joint stock company incorporated in the Kingdom of Saudi Arabia under commercial register number 1010257812 having its registered office at Tatweer Towers, P.O. Box 75724, Riyadh 11588, Kingdom of Saudi Arabia. UBS Saudi Arabia is authorized and regulated by the Capital Market Authority to conduct securities business under license number 08113-37.

Dubai: The information distributed by UBS AG Dubai Branch is intended for Professional Clients only and is not for further distribution within the United Arab Emirates.

United States: Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a "non-US affiliate") to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a document prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities mentioned in this document must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. UBS Securities LLC is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule"), and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule.

Canada: Distributed by UBS Securities Canada Inc., a registered investment dealer in Canada and a Member-Canadian Investor Protection Fund, or by another affiliate of UBS AG that is registered to conduct business in Canada or is otherwise exempt from registration.

Mexico: This report has been distributed and prepared by UBS Casa de Bolsa, S.A. de C.V., UBS Grupo Financiero, an entity that is part of UBS Grupo Financiero, S.A. de C.V. and is an affiliate of UBS AG. This document is intended for distribution to institutional or sophisticated investors only. Research reports only reflect the views of the analysts responsible for the reports. Analysts do not receive any compensation from persons or entities different from UBS Casa de Bolsa, S.A. de C.V., UBS Grupo Financiero, or different from entities belonging to the same financial group or business group of such. For Spanish translations of applicable disclosures, please see www.ubs.com/disclosures.

Brazil: Except as otherwise specified herein, this material is prepared by UBS Brasil CCTVM S.A. to persons who are eligible investors residing in Brazil, which are considered to be: (i) financial institutions, (ii) insurance firms and investment capital companies, (iii) supplementary pension entities, (iv) entities that hold financial investments higher than R\$300,000.00 and that confirm the status of qualified investors in written, (v) investment funds, (vi) securities portfolio managers and securities consultants duly authorized by Comissão de Valores Mobiliários (CVM), regarding their own investments, and (vii) social security systems created by the Federal Government, States, and Municipalities.

Hong Kong: Distributed by UBS Securities Asia Limited and/or UBS AG, Hong Kong Branch.

Singapore: Distributed by UBS Securities Pte. Ltd. [MCI (P) 018/09/2015 and Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Please contact UBS Securities Pte. Ltd., an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110); or UBS AG, Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or document. The recipients of this document represent and warrant that they are accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289).

Japan: Distributed by UBS Securities Japan Co., Ltd. to professional investors (except as otherwise permitted). Where this document has been prepared by UBS Securities Japan Co., Ltd., UBS Securities Japan Co., Ltd. is the author, publisher and distributor of the document. Distributed by UBS AG, Tokyo Branch to Professional Investors (except as otherwise permitted) in relation to foreign exchange and other banking businesses when relevant.

Australia: Clients of UBS AG: Distributed by UBS AG (Holder of Australian Financial Services License No. 231087). Clients of UBS Securities Australia Ltd: Distributed by UBS Securities Australia Ltd (Holder of Australian Financial Services License No. 231098). This document contains general information and/or general advice only and does not constitute personal financial product advice. As such, the information in this document has been prepared without taking into account any investor's objectives, financial situation or needs, and investors should, before acting on the information, consider the appropriateness of the information, having regard to their objectives, financial situation and needs. If the information contained in this document relates to the acquisition, or potential acquisition of a particular financial product by a 'Retail' client as defined by section 761G of the Corporations Act 2001 where a Product Disclosure Statement would be required, the retail client should obtain and consider the Product Disclosure Statement relating to the product before making any decision about whether to acquire the product. The UBS Securities Australia Limited Financial Services Guide is available at: www.ubs.com/ecs-research-fsg.

New Zealand: Distributed by UBS New Zealand Ltd. The information and recommendations in this publication are provided for general information purposes only. To the extent that any such information or recommendations constitute financial advice, they do not take into account any person's particular financial situation or goals. We recommend that recipients seek advice specific to their circumstances from their financial advisor.

Korea: Distributed in Korea by UBS Securities Pte. Ltd., Seoul Branch. This document may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Seoul Branch.

Malaysia: This material is authorized to be distributed in Malaysia by UBS Securities Malaysia Sdn. Bhd (Capital Markets Services License No.: CMS/A0063/2007). This material is intended for professional/institutional clients only and not for distribution to any retail clients.

India: Distributed by UBS Securities India Private Ltd. (Corporate Identity Number U67120MH1996PTC097299) 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000. It provides brokerage services bearing SEBI Registration Numbers: NSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, NSE (Currency Derivatives Segment) INE230951431, BSE (Capital Market Segment) INB010951437; merchant banking services bearing SEBI Registration Number: INM000010809 and Research Analyst services bearing SEBI Registration Number: INH000001204. UBS AG, its affiliates or subsidiaries may have debt holdings or positions in the subject Indian company/companies. Within the past 12 months, UBS AG, its affiliates or subsidiaries may have received compensation for non-investment banking securities-related services and/or non-securities services from the subject Indian company/companies. The subject company/companies may have been a client/clients of UBS AG, its affiliates or subsidiaries during the 12 months preceding the date of distribution of the research report with respect to investment banking and/or non-investment banking securities-related services and/or non-securities services. With regard to information on associates, please refer to the Annual Report at: http://www.ubs.com/global/en/about_ubs/investor_relations/annualreporting.html

The disclosures contained in research documents produced by UBS Limited shall be governed by and construed in accordance with English law.

UBS specifically prohibits the redistribution of this document in whole or in part without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. Images may depict objects or elements that are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2016. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

